RxDoctor Payments Data

Sandra Worrell, MD

Family Medicine · West Burlington, IANPI 1285841775

Payments from drug & device makers

$299in general payments, 2019–2025

Across 10 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$185
  • Axonics, Inc.$24
  • Vistapharm, Inc.$22
  • Vertex$19
  • Lilly USA, LLC$19
  • AstraZeneca$17
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$299100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott4$185
Axonics, Inc.1$24
Vistapharm, Inc.1$22
Vertex1$19
Lilly USA, LLC1$19
AstraZeneca1$17
AbbVie1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$299 in reported general payments places this provider in the 65th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$113,037
Medicare patients
409
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$70,064
OzempicSemaglutide40$48,409
JardianceEmpagliflozin43$43,987
TrulicityDulaglutide21$38,207
FarxigaDapagliflozin Propanediol28$25,033
XareltoRivaroxaban13$21,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$20,517
RybelsusSemaglutide13$19,939
MounjaroTirzepatide12$14,892
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$13,622
Breo ElliptaFluticasone/Vilanterol15$9,883
Lantus SolostarInsulin Glargine,hum.Rec.Anlog62$8,070
Tresiba Flextouch U-100Insulin Degludec16$8,011
MyrbetriqMirabegron16$7,656
BrilintaTicagrelor13$6,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$19$53,09933 claims
AstraZenecaFarxiga, Brilinta, Symbicort$17$36,82262 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in West Burlington

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →